OVERVIEW

Oncology Consultations® in Ovarian Cancer: Differentiating Among Clinical Trial Designs to Match PARP to Patient is organized by Physicians' Education Resource, LLC (PER). This Conference has been approved for a maximum of 1.5 AMA PRA Category 1 Credits™.

Release Date: October 31, 2018
Expiration Date: October 31, 2019

Target Audience:
This activity is directed toward medical oncologists, gynecologic oncologists, radiation oncologists, surgical oncologists, and other health care professionals who manage and treat patients with ovarian cancer.

Activity Overview:
This activity, Oncology Consultations® in Ovarian Cancer: Differentiating Among Clinical Trial Designs to Match PARP to Patient, developed in the Physicians’ Education Resource, LLC, (PER®) established Oncology Consultations® legacy format, focuses on the landscape of clinical trial design and key data guiding the use of PARP inhibitors in ovarian cancer. This presentation features Dr. Susana Campos and Dr. Shannon Westin reviewing the study designs that led to current and emerging indications for the use of PARP inhibitors and discussing ongoing clinical trials in this field. Throughout this activity, they provide their expert viewpoints on the role of PARP inhibitors in ovarian cancer, including placing cutting-edge data into the context of case-based discussion to guide the use of PARP inhibitors for treatment of your patients.

Educational Objectives:
At the conclusion of this activity, you should be better prepared to:
• Differentiate among recent clinical trials of PARP inhibitors with respect to trial design and clinical outcomes
• Develop strategies to recognize and manage adverse events of PARP inhibitor therapies among patients with ovarian cancer
• Utilize knowledge of clinical trial designs, results, and patient-specific characteristics to personalize a treatment plan in the care of patients with ovarian cancer